Insight Molecular Diagnostics Inc (IMDX)

$4.20 +0.22 (5.53%)
Market Cap 137.44M
Revenue (ttm) 4.06M
Net Income (ttm) -50.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,236.95%
Debt to Equity Ratio 0.00
Volume 173,800
Avg Vol 194,196
Day's Range N/A - N/A
Shares Out 32.72M
Stochastic %K 80%
Beta 1.80
Analysts Sell
Price Target $8.33

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
RUNNINWILD
RUNNINWILD Sep. 6 at 12:25 PM
$IMDX https://stocks.apple.com/AZ6acyux3TlqTmhD7C9Oegg
0 · Reply
JohnPDaly
JohnPDaly Sep. 3 at 7:11 PM
$IMDX binary is a bit frightening, but here we are. Good luck my friends.
0 · Reply
Bogwood
Bogwood Aug. 28 at 4:45 PM
$IMDX Odd they haven't announced the raise yet. Usually it'd be pretty quick after 1x1 meetings, but I don't think it means they're confident in getting approval before the cash red-lines
1 · Reply
RUNNINWILD
RUNNINWILD Aug. 26 at 9:15 PM
$IMDX steady, lads , steady
0 · Reply
JohnPDaly
JohnPDaly Aug. 17 at 4:39 PM
$IMDX better cheaper faster.
0 · Reply
Logic102
Logic102 Aug. 17 at 4:11 PM
$IMDX I was pleased with the event. An actual cardiologist using the product and other versions of similar products gave pragmatic answers about Graft Assure having definite advantages for patients and physicians.
0 · Reply
Logic102
Logic102 Aug. 17 at 2:52 PM
$IMDX Event starts in 7 minutes, should give more color.
0 · Reply
topstockalerts
topstockalerts Aug. 15 at 12:01 AM
$IMDX the move looks more deliberate than random.
0 · Reply
Logic102
Logic102 Aug. 14 at 2:44 PM
$IMDX Back in near the close and in the after hours yesterday. This may be a somewhat risky stock, but I really like the Risk/Reward formula. The upside is huge at this tiny M Cap.
1 · Reply
JohnPDaly
JohnPDaly Aug. 14 at 1:57 PM
$IMDX fuckery.
0 · Reply
Latest News on IMDX
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

Sep 2, 2026, 8:00 AM EDT - 11 days ago

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

Insight Molecular Diagnostics initiated with a Buy at Lucid Capital

2026-08-24T10:15:27.000Z - 20 days ago

Insight Molecular Diagnostics initiated with a Buy at Lucid Capital

Insight Molecular Diagnostics Transcript: KOL event

Aug 17, 2026, 11:00 AM EDT - 27 days ago

Insight Molecular Diagnostics Transcript: KOL event

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

Aug 11, 2026, 4:05 PM EDT - 4 weeks ago

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026

Aug 10, 2026, 5:00 PM EDT - 4 weeks ago

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026

Insight Molecular Diagnostics Shareholder letter: Q2 2026

Aug 10, 2026, 5:00 PM EDT - 4 weeks ago

Insight Molecular Diagnostics Shareholder letter: Q2 2026

Insight Molecular Diagnostics Earnings release: Q2 2026

Aug 10, 2026, 5:00 PM EDT - 4 weeks ago

Insight Molecular Diagnostics Earnings release: Q2 2026

Insight Molecular Diagnostics Quarterly report: Q2 2026

Aug 10, 2026, 5:00 PM EDT - 4 weeks ago

Insight Molecular Diagnostics Quarterly report: Q2 2026

Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)

2026-08-10T20:46:18.000Z - 4 weeks ago

Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)

Insight Molecular Diagnostics Slides: Investor presentation

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

Insight Molecular Diagnostics Slides: Investor presentation

iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference

Aug 4, 2026, 7:00 AM EDT - 5 weeks ago

iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference

Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay

2026-07-23T13:30:33.000Z - 7 weeks ago

Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Jul 23, 2026, 8:00 AM EDT - 7 weeks ago

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Jul 16, 2026, 3:22 PM EDT - 1 month ago

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Jun 29, 2026, 8:00 AM EDT - 2 months ago

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Jun 22, 2026, 2:07 PM EDT - 2 months ago

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Jun 16, 2026, 4:05 PM EDT - 2 months ago

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Jun 11, 2026, 4:17 PM EDT - 3 months ago

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Jun 9, 2026, 4:05 PM EDT - 3 months ago

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026

May 13, 2026, 5:00 PM EDT - 4 months ago

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026

Insight Molecular Diagnostics Earnings release: Q1 2026

May 13, 2026, 5:00 PM EDT - 4 months ago

Insight Molecular Diagnostics Earnings release: Q1 2026

Insight Molecular Diagnostics Shareholder letter: Q1 2026

May 13, 2026, 5:00 PM EDT - 4 months ago

Insight Molecular Diagnostics Shareholder letter: Q1 2026

Insight Molecular Diagnostics Quarterly report: Q1 2026

May 13, 2026, 5:00 PM EDT - 4 months ago

Insight Molecular Diagnostics Quarterly report: Q1 2026

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

May 13, 2026, 4:05 PM EDT - 4 months ago

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Insight Molecular Diagnostics Slides: Investor presentation

May 13, 2026, 4:00 PM EDT - 4 months ago

Insight Molecular Diagnostics Slides: Investor presentation

iMDx to Release First Quarter 2026 Results on May 13, 2026

May 6, 2026, 4:05 PM EDT - 4 months ago

iMDx to Release First Quarter 2026 Results on May 13, 2026

Insight Molecular Diagnostics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Insight Molecular Diagnostics Proxy statement: Proxy filing

Insight Molecular Diagnostics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Insight Molecular Diagnostics Proxy statement: Proxy filing

Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 9:30 AM EDT - 5 months ago

Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025

Insight Molecular Diagnostics Shareholder letter: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

Insight Molecular Diagnostics Shareholder letter: Q4 2025

Insight Molecular Diagnostics Annual report: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

Insight Molecular Diagnostics Annual report: Q4 2025

Insight Molecular Diagnostics Earnings release: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

Insight Molecular Diagnostics Earnings release: Q4 2025

Insight Molecular Diagnostics submits GraftAssureDx for FDA review

2026-03-26T20:51:47.000Z - 5 months ago

Insight Molecular Diagnostics submits GraftAssureDx for FDA review

Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year

2026-03-26T20:45:14.000Z - 5 months ago

Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Mar 26, 2026, 4:05 PM EDT - 5 months ago

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Insight Molecular Diagnostics Slides: Investor presentation

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Insight Molecular Diagnostics Slides: Investor presentation

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

Mar 20, 2026, 8:00 AM EDT - 5 months ago

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

Insight Molecular Diagnostics highlights publication of study on GraftAssure

2026-03-13T12:13:12.000Z - 6 months ago

Insight Molecular Diagnostics highlights publication of study on GraftAssure

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score

Insight Molecular Diagnostics completes milestones advancing GraftAssureDx

2026-03-03T13:21:06.000Z - 6 months ago

Insight Molecular Diagnostics completes milestones advancing GraftAssureDx

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Mar 3, 2026, 8:00 AM EST - 6 months ago

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street

2026-02-17T13:50:59.000Z - 6 months ago

Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street

Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering

2026-02-11T13:23:15.000Z - 7 months ago

Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering

iMDx Announces $26.0 Million Registered Direct Offering

Feb 11, 2026, 8:00 AM EST - 7 months ago

iMDx Announces $26.0 Million Registered Direct Offering

Insight ‘congratulated’ STAR working group on organ health testing paper

2026-01-13T14:13:54.000Z - 8 months ago

Insight ‘congratulated’ STAR working group on organ health testing paper

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 13, 2026, 9:00 AM EST - 8 months ago

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Jan 7, 2026, 4:05 PM EST - 8 months ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs

2026-01-06T13:05:54.000Z - 8 months ago

Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Jan 6, 2026, 8:00 AM EST - 8 months ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

iMDx prepares for U.S. commercial launch of GraftAssureDx

2026-01-05T12:11:39.000Z - 8 months ago

iMDx prepares for U.S. commercial launch of GraftAssureDx

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Jan 5, 2026, 7:00 AM EST - 8 months ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Insight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year

2025-11-10T22:10:29.000Z - 10 months ago

Insight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year

Insight Molecular Diagnostics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Insight Molecular Diagnostics Earnings Call Transcript: Q3 2025

Insight Molecular Diagnostics Shareholder letter: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Insight Molecular Diagnostics Shareholder letter: Q3 2025

Insight Molecular Diagnostics Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Insight Molecular Diagnostics Quarterly report: Q3 2025

Insight Molecular Diagnostics Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Insight Molecular Diagnostics Earnings release: Q3 2025

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 10, 2025, 4:05 PM EST - 10 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Nov 3, 2025, 4:05 PM EST - 10 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 13, 2025, 4:05 PM EDT - 11 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Insight Molecular says kidney transplant patient achieved ‘immune reset’

2025-10-06T11:35:23.000Z - 11 months ago

Insight Molecular says kidney transplant patient achieved ‘immune reset’

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Oct 6, 2025, 7:15 AM EDT - 11 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Insight Molecular Diagnostics announces attendance at two industry conferences

2025-09-24T11:15:23.000Z - 11 months ago

Insight Molecular Diagnostics announces attendance at two industry conferences

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 24, 2025, 7:05 AM EDT - 11 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Slides: Investor presentation

Sep 16, 2025, 7:00 AM EDT - 12 months ago

Insight Molecular Diagnostics Slides: Investor presentation

Insight Molecular Diagnostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Insight Molecular Diagnostics announces novel registry database

2025-09-08T11:25:06.000Z - 1 year ago

Insight Molecular Diagnostics announces novel registry database

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:15 AM EDT - 1 year ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Insight Molecular Diagnostics enrolls first patient in GraftAssureDx trial

2025-09-08T11:10:23.000Z - 1 year ago

Insight Molecular Diagnostics enrolls first patient in GraftAssureDx trial

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Sep 8, 2025, 7:00 AM EDT - 1 year ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 26, 2025, 4:05 PM EDT - 1 year ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Insight Molecular Diagnostics Transcript: KOL event

Aug 15, 2025, 4:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Transcript: KOL event

Insight Molecular Diagnostics Slides: KOL event

Aug 15, 2025, 4:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Slides: KOL event

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2025

Insight Molecular Diagnostics Shareholder letter: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Shareholder letter: Q2 2025

Insight Molecular Diagnostics Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Quarterly report: Q2 2025

Insight Molecular Diagnostics Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings release: Q2 2025

Insight Molecular Diagnostics Slides: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Slides: Q2 2025

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 11, 2025, 4:05 PM EDT - 1 year ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Aug 4, 2025, 4:05 PM EDT - 1 year ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 30, 2025, 4:05 PM EDT - 1 year ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jul 28, 2025, 4:05 PM EDT - 1 year ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Insight Molecular Diagnostics announces results from test kit technology study

2025-06-23T20:15:43.000Z - 1 year ago

Insight Molecular Diagnostics announces results from test kit technology study

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 1 year ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 1 year ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

Insight Molecular Diagnostics Proxy statement: Proxy Filing

May 14, 2025, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Proxy statement: Proxy Filing

Insight Molecular Diagnostics Proxy statement: Proxy Filing

May 14, 2025, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Proxy statement: Proxy Filing

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2025

Insight Molecular Diagnostics Shareholder letter: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Shareholder letter: Q1 2025

Insight Molecular Diagnostics Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings release: Q1 2025

Insight Molecular Diagnostics Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Quarterly report: Q1 2025

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 1 year ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 1 year ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 1 year ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Insight Molecular Diagnostics Registration statement: Registration Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Registration statement: Registration Filing

Insight Molecular Diagnostics Earnings Call Transcript: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings Call Transcript: Q4 2024

Insight Molecular Diagnostics Shareholder letter: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Shareholder letter: Q4 2024

Insight Molecular Diagnostics Annual report: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Annual report: Q4 2024

Insight Molecular Diagnostics Earnings release: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Earnings release: Q4 2024

Insight Molecular Diagnostics Slides: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Insight Molecular Diagnostics Slides: Q4 2024

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 1 year ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Insight Molecular Diagnostics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Insight Molecular Diagnostics Earnings Call Transcript: Q3 2024

Insight Molecular Diagnostics Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Insight Molecular Diagnostics Earnings release: Q3 2024

Insight Molecular Diagnostics Shareholder letter: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Insight Molecular Diagnostics Shareholder letter: Q3 2024

Insight Molecular Diagnostics Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Insight Molecular Diagnostics Quarterly report: Q3 2024

Insight Molecular Diagnostics Slides: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Insight Molecular Diagnostics Slides: Q3 2024

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Insight Molecular Diagnostics Transcript: 17th Annual LD Micro Main Event Conference

Oct 29, 2024, 5:30 PM EDT - 1 year ago

Insight Molecular Diagnostics Transcript: 17th Annual LD Micro Main Event Conference

Insight Molecular Diagnostics Registration statement: Registration Filing

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Registration statement: Registration Filing

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Insight Molecular Diagnostics Registration statement: Registration Filing

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Registration statement: Registration Filing

Insight Molecular Diagnostics Proxy statement: Proxy Filing

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Insight Molecular Diagnostics Proxy statement: Proxy Filing

Insight Molecular Diagnostics Transcript: Sidoti Micro-Cap Virtual Conference

Aug 14, 2024, 1:00 PM EDT - 2 years ago

Insight Molecular Diagnostics Transcript: Sidoti Micro-Cap Virtual Conference

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Insight Molecular Diagnostics Earnings Call Transcript: Q2 2024

Insight Molecular Diagnostics Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Insight Molecular Diagnostics Quarterly report: Q2 2024

Insight Molecular Diagnostics Earnings release: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Insight Molecular Diagnostics Earnings release: Q2 2024

Insight Molecular Diagnostics Slides: Investor Presentation

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Insight Molecular Diagnostics Slides: Investor Presentation

Insight Molecular Diagnostics Registration statement: Registration Filing

Aug 1, 2024, 8:00 AM EDT - 2 years ago

Insight Molecular Diagnostics Registration statement: Registration Filing

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 2 years ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 2 years ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Insight Molecular Diagnostics Registration statement: Registration Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Insight Molecular Diagnostics Registration statement: Registration Filing

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Insight Molecular Diagnostics Earnings Call Transcript: Q1 2024

Insight Molecular Diagnostics Quarterly report: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Insight Molecular Diagnostics Quarterly report: Q1 2024

Insight Molecular Diagnostics Earnings release: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Insight Molecular Diagnostics Earnings release: Q1 2024

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 2 years ago

Oncocyte Reports First Quarter 2024 Financial Results

RUNNINWILD
RUNNINWILD Sep. 6 at 12:25 PM
$IMDX https://stocks.apple.com/AZ6acyux3TlqTmhD7C9Oegg
0 · Reply
JohnPDaly
JohnPDaly Sep. 3 at 7:11 PM
$IMDX binary is a bit frightening, but here we are. Good luck my friends.
0 · Reply
Bogwood
Bogwood Aug. 28 at 4:45 PM
$IMDX Odd they haven't announced the raise yet. Usually it'd be pretty quick after 1x1 meetings, but I don't think it means they're confident in getting approval before the cash red-lines
1 · Reply
RUNNINWILD
RUNNINWILD Aug. 26 at 9:15 PM
$IMDX steady, lads , steady
0 · Reply
JohnPDaly
JohnPDaly Aug. 17 at 4:39 PM
$IMDX better cheaper faster.
0 · Reply
Logic102
Logic102 Aug. 17 at 4:11 PM
$IMDX I was pleased with the event. An actual cardiologist using the product and other versions of similar products gave pragmatic answers about Graft Assure having definite advantages for patients and physicians.
0 · Reply
Logic102
Logic102 Aug. 17 at 2:52 PM
$IMDX Event starts in 7 minutes, should give more color.
0 · Reply
topstockalerts
topstockalerts Aug. 15 at 12:01 AM
$IMDX the move looks more deliberate than random.
0 · Reply
Logic102
Logic102 Aug. 14 at 2:44 PM
$IMDX Back in near the close and in the after hours yesterday. This may be a somewhat risky stock, but I really like the Risk/Reward formula. The upside is huge at this tiny M Cap.
1 · Reply
JohnPDaly
JohnPDaly Aug. 14 at 1:57 PM
$IMDX fuckery.
0 · Reply
RUNNINWILD
RUNNINWILD Aug. 14 at 1:43 PM
$IMDX these foolish games
0 · Reply
TI7812
TI7812 Aug. 13 at 11:59 PM
$BCRX $IMDX anyone find a reason for the selling? I have not. just two of many biotechs I follow
2 · Reply
Wisenheimer
Wisenheimer Aug. 13 at 9:24 PM
$IMDX we will see another capital raise $3 or lower
0 · Reply
JohnPDaly
JohnPDaly Aug. 13 at 8:30 PM
$IMDX bought more.
0 · Reply
Logic102
Logic102 Aug. 13 at 7:56 PM
$IMDX I have been watching this name from the sidelines recently and now it's beaten to heck all of a sudden. Tell me why I should be a buyer and how in the world it has taken such a plunge the past several days when it has Medicare approval to sell if/when it gets its FDA approval soon.
0 · Reply
jackedmund99
jackedmund99 Aug. 13 at 7:51 PM
$IMDX hi whoever wanted the fuck out just flush the Stock down the toilet -  with all the great things happening and addressing a $2 billion plus marketplace nobody’s got patience so fuck up get the fuck out I’m buying more just bought 10,000 trying to buy another five
0 · Reply
jackedmund99
jackedmund99 Aug. 13 at 7:35 PM
$IMDX he’s shaking his Stock out because institutions want it. They’re the buyers they’re the buyers they’re buying all the little shares whoever selling the stock is really stupid cause I can’t read between the lines a year from now they’re gonna be kicking themselves. Read the trades. publications read what’s going on out there in the real world and stop worrying about the stock price.
0 · Reply
jackedmund99
jackedmund99 Aug. 13 at 7:30 PM
$IMDX whoever is selling is just stupid
0 · Reply
jackedmund99
jackedmund99 Aug. 13 at 7:30 PM
$IMDX thanks for another 10k shares cost 3.89
0 · Reply
NY2CHI
NY2CHI Aug. 13 at 6:24 PM
$IMDX market is trying to shake the weak hands before the FDA decision....I'll be stepping in to load more as this drop continues.
0 · Reply
RUNNINWILD
RUNNINWILD Aug. 12 at 4:21 PM
$IMDX steady now lads
0 · Reply
Bogwood
Bogwood Aug. 10 at 11:04 PM
$IMDX It's doomed. SIR meeting has the potential to push approval out by another quarter, so not seeing the data package resubmitted by now becomes a q of how big the next dilution will be. I had an egregiously large 25% port weight, so content with a partial sale now and repurchase after approval
1 · Reply